External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma

Inclusion Criteria:

* Intermediate or high grade sarcoma as determined by pathology review
* Musculoskeletal tumor in extremities, trunk or chest wall.
* Primary tumor or isolated locally recurrent tumor greater than 5 cm in diameter.
* Clinical Stage T2N0M0 (AJCC 6th edition)
* Patient is not a candidate for neoadjuvant chemotherapy.
* Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1.
* No steroid therapy within 4 weeks of first dendritic cell administration.
* No coagulation disorder.
* Patient's written informed consent.
* No contraindication to resection.
* Adequate organ function (measured within a week of beginning treatment).

  * White blood count (WBC) \> 3,000/mm to the third power and absolute neutrophil count (ANC) \>1500/mm to the third power
  * Platelets \> 100,000/mm to the third power
  * Hematocrit \> 25%
  * Bilirubin \< 2.0 mg/dL
  * Creatinine \< 2.0 mg/dL, or creatinine clearance \> 60 mL/min
* Radiation Oncologist must confirm that a 2-3 cm strip of skin can be spared from radiation.

Exclusion Criteria:

* Retroperitoneal location.
* Gastrointestinal stromal tumor (GIST).
* Demonstrated metastatic disease.
* Prior radiation therapy if the current tumor is locally recurrent after prior resection.
* Concurrent treatment with any anticancer agent other than radiation as dictated by the protocol.
* Bleeding disorder.
* H.I.V. infection or other primary immunodeficiency disorder.
* Ongoing systemic therapy with immunosuppressant drugs (e.g. corticosteroids, azathioprine, cyclosporin, methotrexate).
* Any serious ongoing infection.
* Pregnant or lactating women -- Patients in reproductive age must agree to use contraceptive methods for the duration of the study (a pregnancy test will be obtained before treatment).
* ECOG performance status of 2, 3 or 4.